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8facilitates apoptosis by targeting several anti-apoptotic
genes. If miR-466h-5p activation is demonstrated to be
a universal early response in apoptotic pathways in CHO,
2 Mu¨ ller, D. et al. (2008) MicroRNAs as targets for engineering of CHO
cell factories. Trends Biotechnol. 26, 359–365
3 Xu, X. et al. (2011) The genomic sequence of the Chinese hamster ovar
(CHO)-K1 cell line. Nat. Biotechnol. 29, 735–741
4 Becker, J. et al. (2011) Unraveling the Chinese hamster ovary cell lin
transcriptome by next-generation sequencing. J. Biotechnol. 156
227–235
5 Hackl, M. et al. (2011) Next-generation sequencing of the Chines
hamster ovary microRNA transcriptome: identification, annotatio
and profiling of microRNAs as targets for cellular engineering. J
Biotechnol. 153, 62–75
6 Hackl, M. et al. (2012) Computational identification of microRNA gen
loci and precursor microRNA sequences in CHO cell lines. J
Biotechnol. 158, 151–155
7 Gammell, P. et al. (2007) Initial identification of low temperature an
culture stage induction of miRNA expression in suspension CHO-K
cells. J. Biotechnol. 130, 213–218
Box 1. Biogenesis and function of microRNAs
miRNAs are small noncoding RNAs between 18 and 24 nucleotides
in length that are transcribed either individually or in clusters from
RNA polymerase II (RNA Pol II) promoters, yielding a primary
transcript. These transcripts undergo sequential cleavage of Drosha
and Dicer, inside and outside the cell nucleus, respectively. The
mature miRNA generated by Dicer cleavage can target a protein
complex (RNA-induced silencing complex, RISC) to various mRNA
sequences harboring complementary sequences, which results in
translational repression or mRNA destabilization [15].
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-its targeted deletion or repression could result in stress
resistant CHO cells.
Based on these initial exciting proofs-of-principle of the
functional importance of CHO miRNAs and the tools tha
are at hand now, including genomics (miRNA sequences)
transcriptomics (profiling techniques), and proteomic
(target identification), further breakthroughs are soon to
be expected. Furthermore, because miRNAs are only one o
many noncoding RNA species that do not add onto the
translational burden that recombinant producer cells al
ready have to bear, we are convinced that other noncoding
RNAs will hold additional promises for engineering the
‘perfect’ host cell.
Acknowledgments
M.H. is supported by BOKU DOC. J.G. is supported by Genome Austri
(GENAU), Austrian Science Fund Fonds zur Fo¨rderung der Wissenschaf
und Forschung (FWF), Herzfeldersche Familienstiftung, and Centre d
Recherche et d’Investigation sensorielle de Chanel (CERIES). J.G. an
N.B. are supported by the FWF Doctoral Program BioTop W1224.
References
1 Hobert, O. (2008) Gene regulation by transcription factors an
microRNAs. Science 319, 1785–1786
Next generation stent coa
biotechnology and nanote
Aaron Tan1, Mohammad S. Alavijeh2 an
1Centre for Nanotechnology and Regenerative Medicine, UCL
London, London, UK
2Pharmidex Pharmaceutical Services Ltd, London, UK
3Royal Free Hampstead NHS Trust Hospital, London, UK
The advent of percutaneous coronary intervention (PCI) a
a less invasive method to coronary artery bypass graf
(CABG) surgery has revolutionized the field of interven
tional cardiology. The use of metal stents as supporting
structures, in addition to balloon angioplasty, for main
taining the patency of blocked coronary vessels waCorresponding author: Seifalian, A.M. (a.seifalian@ucl.ac.uk).
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first pioneered in 1986 [1]. Before the introduction o
drug-eluting stents (DES), bare-metal stents (BMS) were
the mainstay in coronary stenting procedures. Indeed, coro
nary stenting accounted for 84.2% of all PCI procedures in
1999, and by 2005, 90% of stenting procedures were made
using a DES [2]. DES had the added advantage of having
anti-proliferative drugs on them, thus circumventing the
problem of in-stent restenosis due to intimal hyperplasia
Box 1. Convergence of biofunctionalized polymers, controlled drug
To address the problems seen in BMS and DES, the next generation
cardiovascular stent could involve coating with special nanocompo-
site polymers such as POSS-PCU (Figure I). To enhance endothelia-
lization, EPC-specific antibodies could be attached to the polymer. NO
is essential for maintaining a healthy endothelium and preventing
thrombosis, and NO-eluting polymers could also be developed.
Multiple drugs could be incorporated using LbL coating technology
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nalized nanocomposite polymers, endothelial progenitor cell capture technology,
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Figure I. A three-pronged approach for next generation coronary stents: biofunctiolayer-by-layer controlled drug release.
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ntrolled release. Abbreviations: EPC, endothelial progenitor cell;
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TRENDS in Biotechnology Table I. Stent coatings incorporating nanotechnology
Novel stent coatings Overviewa
LbL (for tunable and multiple
drug release)
Ability to release multiple drug types in a controlled manner
Potential to incorporate both anti-proliferative and anti-thrombogenic agents
Can be fine-tuned to match vessel healing times
Can be biofunctionalized with bioactive molecules such as NO, DNA, and antibodies
Antibody (for endothelialization) Anti-CD34 antibodies for EPC capture (e.g., GenousTM stent by OrbusNeich)
Other antibodies like anti-CD133 and VEGFR-2 are currently being explored
Peptide (for endothelialization
and anti-thrombogenicity)
Synthetic functional peptides such as RGD and PA nanofibers can expedite rate of endothelialization
GP IIb/IIIa integrin complex to prevent platelet aggregation and thrombosis
NO (for anti-proliferative and
anti-thrombogenic effects)
NO precursors and donors (e.g., SNP and GSNO) can be integrated into polymer coatings
NO would be released upon contact with physiological fluids conferring anti-proliferative and
anti-thrombogenicity effects
Nanoparticle-eluting
(for endothelialization
Utilization of nanoparticles can increase therapeutic index
Encapsulation of pharmacologic agents into liposomes can confer sustained intracytoplasmic releaseand enhanced drug delivery) Magnetic nanoparticles can be g
drug localization and delivery
Gene-eluting (for mitigating
in-stent restenosis and augmenting
re-endothelialization)
Plasmid DNA expressing eNOS a
re-endothelialization
Gene therapy can be delivered v
aAbbreviations: LbL, layer-by-layer; NO, nitric oxide; VEGFR-2, vascular endothe
amphiphile; GP, glycoprotein; SNP, sodium nitroprusside; GSNO, S-nitrosoglutathiod to the stent area, increasing re-endothelialization and enhanced
iNOS can inhibit smooth muscle cell proliferation and augment
denoviruses or liposomes localized on stents
growth factor receptor 2; RGD, arginine-glycine aspartic acid; PA, peptide
eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase.407
seen in BMS. However, the use of DES engendered yet
another potentially life-threatening complication: late stent
thrombosis (ST). Although not fully elucidated, polymer/
drug coating hypersensitivity and lack of endothelialization
are thought to contribute to ST. Hence, the advancement
and convergence of nanotechnology and biotechnology
has recently been explored for optimizing stent coatings
(Box 1).
The properties of ideal stent coatings are: (i) biocompat-
ibility, (ii) a non-biodegradable polymer basecoat to pre-
vent blood from coming into contact with metal struts,
(iii) anti-thrombogenicity, (iv) anti-calcification effects,
(v) ability to interface with anti-proliferative drugs to
prevent in-stent restenosis, (vi) superior mechanical prop-
erties to withstand stent apposition without polymer frac-
ture, and (vii) the surface topography must be favorable for
endothelialization to occur. We have developed and pat-
ented a proprietary nanocomposite polymer, polyhedral
oligomeric silsesquioxane poly (carbonate-urea) urethane
(POSS-PCU), which appears to fulfill the above-mentioned
criteria. More significantly, POSS-PCU was recently used
as the scaffold material in the world’s first synthetic tra-
chea transplant in a patient [3].
Sustained and controlled release of drugs is an impor-
tant aspect in regenerative medicine. One way for achiev-
ing this is a technique called layer-by-layer (LbL) self
assembly for tunable drug release in thin films [4]. It
has been shown that LbL coatings on stents promote
endothelialization and attenuate thrombosis. Having tun-
able release allows the drug delivery rate to be matched
with healing time. Therefore, a plethora of drugs can be
simultaneously incorporated onto stent coatings, including
anti-proliferative, anti-thrombogenic, and anti-platelet
agents to mitigate problems seen in the current range of
BMS and DES.
Endothelialization is a process whereby endothelial
progenitor cells (EPCs) adhere and proliferate on a surface
to form a confluent layer of endothelium. It is imperative
for endothelialization to occur on a stented vessel to pre-
vent thrombosis. Promoting endothelialization can also be
upregulated by conjugating antibodies on stent surfaces.
This has been exemplified by the GenousTM stent (Orbus-
Neich), which uses an EPC-specific anti-CD34 antibody [5].
Furthermore, the new GenousTM Combo stent, which also
features drug release in addition to EPC capture technology,
demonstrated favorable results in a clinical trial (see:
http://www.prnewswire.com/news-releases/remedee-study-
meets-primary-endpoint-orbusneichs-combo-dual-therapy-
stent-is-non-inferior-to-des-133807003.html). Using the
same concept, functional peptides sequences like RRE-
TAWA [6] and peptide amphiphile nanofibers [7] can pro-
mote endothelial cell adhesion and proliferation.
Nitric oxide (NO) is widely recognized to play a signifi-
cant role in vessel homeostasis. NO donors like sodium
nitroprusside (SNP) can be incorporated into polymers,
and it has the propensity to reduce neointimal hyperplasia
[8]. The use of nanotechnology for nano-encapsulation of
drug molecules into discrete particles is an exciting and
rapidly advancing field. To increase therapeutic index and
to facilitate sustained release of pharmacologic agents,
nanoparticle-eluting stents can be developed to embody
this [9]. Gene-eluting stents have also been proposed as a
novel way of delivering genes encoding endothelial and
inducible nitric oxide synthase (eNOS and iNOS) for the
production of NO [10]. Nanoparticles such as liposomes can
be used to encapsulate genetic material for localized gene
delivery. These gene-eluting stents demonstrated the
ability to inhibit smooth muscle cell proliferation, thereby
limiting restenosis.
At the time of writing, there are 11 FDA-approved DES,
with many of them sharing similar drug/polymer matrix
platforms. The first DES (CYPHER1, Cordis) was ap-
proved in April 2003. Between 2011 and 2012, six DES
were approved. This underscores the significance of DES
in interventional cardiology, which also requires exten-
sive R&D. Given the significant costs involved in R&D and
gaining regulatory approval, the DES market is dominat-
ed by four major industry players: Boston Scientific,
Abbott Vascular, Medtronic, and Cordis. A recent study
by Global Industry Analysts Inc. values the stent market
to reach US $9.8 billion by 2017 (see: http://www.prweb.com/
releases/coronary_stents/bare_metal_drug_eluting/prweb
8961534.htm).
The advent of nanotechnology for biomedical applica-
tions is advancing rapidly. From nanoscale drug formu-
lations, lab-on-a-chip devices, to bioartificial human
organ development [3,11], nanotechnology is poised to
revolutionize biotechnology for medical applications.
Considering that cardiovascular disease is one of the
major killers in the 21st century, optimizing stent
design parameters and coating technologies are of par-
amount importance. It is therefore pertinent to robustly
ascertain the various polymer/drug matrices used in
DES coatings, and the various experimental technolo-
gies being undertaken in developing the next generation
stents.
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